Cargando…

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation

Abiraterone acetate and Enzalutamide are novel anti-androgens that are key treatments to improve both progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. In this study, we aimed to determine whether combinations of AR inhibitors with radia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wright, Timothy C., Dunne, Victoria L., Alshehri, Ali H. D., Redmond, Kelly M., Cole, Aidan J., Prise, Kevin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335570/ https://www.ncbi.nlm.nih.gov/pubmed/34367984 http://dx.doi.org/10.3389/fonc.2021.700543

Ejemplares similares

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
por: Sigorski, Dawid, et al.
Publicado: (2023)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wei, ZhenHeng, et al.
Publicado: (2021)

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience
por: Raju, Rachel, et al.
Publicado: (2021)

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
por: Shah, Yash B., et al.
Publicado: (2022)

Differential responses to (223)Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe
por: Guerra Liberal, Francisco D. C., et al.
Publicado: (2022)

Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
por: Sharova, Evgeniya, et al.
Publicado: (2021)

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer
por: Shah, Yash B., et al.
Publicado: (2022)

Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study
por: Cone, Eugene B., et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
por: Kulkarni, A.A., et al.
Publicado: (2021)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
por: Zhang, Ying, et al.
Publicado: (2022)

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
por: Belic, Jelena, et al.
Publicado: (2018)

Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer
por: Lai, Lillian Y, et al.
Publicado: (2022)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning
por: de Jong, Anouk C., et al.
Publicado: (2023)

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2022)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Chromatin modifications and the DNA damage response to ionizing radiation
por: Kumar, Rakesh, et al.
Publicado: (2013)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
por: Tsao, Phoebe A., et al.
Publicado: (2023)

Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide
por: Johansson, Per, et al.
Publicado: (2023)

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2023)

Ionizing Radiation in Glioblastoma Initiating Cells
por: Rivera, Maricruz, et al.
Publicado: (2013)

Immunomodulation of NK Cells by Ionizing Radiation
por: Chen, Jiarui, et al.
Publicado: (2020)

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021)

Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer
por: Lara, Pedro C., et al.
Publicado: (2022)

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer
por: Torquato, Samantha, et al.
Publicado: (2019)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_motkrkv8cmu1d0ageq4m8g1d7d